142 related articles for article (PubMed ID: 22632263)
1. Diabetic CVD--soluble epoxide hydrolase as a target.
Lorthioir A; Guerrot D; Joannides R; Bellien J
Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):212-22. PubMed ID: 22632263
[TBL] [Abstract][Full Text] [Related]
2. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
3. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Duflot T; Roche C; Lamoureux F; Guerrot D; Bellien J
Expert Opin Drug Discov; 2014 Mar; 9(3):229-43. PubMed ID: 24490654
[TBL] [Abstract][Full Text] [Related]
4. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Bellien J; Joannides R; Richard V; Thuillez C
Pharmacol Ther; 2011 Jul; 131(1):1-17. PubMed ID: 21514320
[TBL] [Abstract][Full Text] [Related]
7. Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.
Duflot T; Moreau-Grangé L; Roche C; Iacob M; Wils J; Rémy-Jouet I; Cailleux AF; Leuillier M; Renet S; Li D; Morisseau C; Lamoureux F; Richard V; Prévost G; Joannidès R; Bellien J
Cardiovasc Diabetol; 2019 Mar; 18(1):35. PubMed ID: 30885203
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
9. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
10. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
12. Epoxides and soluble epoxide hydrolase in cardiovascular physiology.
Imig JD
Physiol Rev; 2012 Jan; 92(1):101-30. PubMed ID: 22298653
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
14. Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy.
Romashko M; Schragenheim J; Abraham NG; McClung JA
Trends Pharmacol Sci; 2016 Nov; 37(11):945-962. PubMed ID: 27633970
[TBL] [Abstract][Full Text] [Related]
15. The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Xu X; Li R; Chen G; Hoopes SL; Zeldin DC; Wang DW
Adv Nutr; 2016 Nov; 7(6):1122-1128. PubMed ID: 28140329
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.
Wu J; Zhao Y; Fan Z; Chen Q; Chen J; Sun Y; Jiang X; Xiao Q
Biochem Biophys Res Commun; 2020 Apr; 524(2):354-359. PubMed ID: 32001002
[TBL] [Abstract][Full Text] [Related]
17. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
18. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
20. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system.
Kuo YM; Lee YH
Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
